In a new deal worth up to $132.5 million, Everest Medicines will have the exclusive right to develop and commercialize zetomipzomib — an experimental treatment for lupus nephritis from Kezar Life Science — in China, South Korea, and other countries in Southeast Asia. Lupus nephritis, or inflammation in the kidneys, is a…
KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting in Geneva, Switzerland, in a poster titled, “…
Kezar Life Sciences, a San Francisco-based company focused on the development of therapies targeting protein homeostasis, recently initiated a Phase 1 clinical trial assessing KZR-616, a potential treatment for multiple autoimmune and inflammatory diseases, including lupus. Together with a medical team in Australia, the study will be performed in a…